Cherry Ma focuses her practice on corporate finance and capital markets. Cherry advises clients on Hong Kong initial public offerings, mergers and acquisitions, regulatory compliance, and general corporate matters.
Public Offerings
- CICC, CCB, CMB, CMS and other underwriters in the approximately US$150 million IPO of Beijing Fourth Paradigm Technology Co., Ltd. (6682.HK) on the Hong Kong Stock Exchange
- Sipai Health Technology Co., Ltd. in its IPO and listing on the Hong Kong Stock Exchange
- 3D Medicines Inc. in its US$52 million IPO and listing on the Hong Kong Stock Exchange
- China VAST Industrial Urban Development (6166.HK) and its controlling shareholder, Profit East Limited, in the US$285 million all-cash take private proposal by China Jinmao Holdings Group Limited (817.HK)
Compliance
- Advising a Hong Kong-listed property management company on the investigation of undisclosed related-party transactions by the Hong Kong Securities and Futures Commission (SFC) and the Hong Kong Stock Exchange, and assisting in the application for resumption of trading
- Advising a Hong Kong-listed company on the investigation by the Hong Kong Stock Exchange regarding to delayed disclosure of annual results and reports, and assisting in the application for resumption of trading
Languages
- English
- Cantonese
- Mandarin
Admissions
- Hong Kong
Education
- The Chinese University of Hong Kong, P.C.L.L.
- The Chinese University of Hong Kong, J.D.; B.A.
Related Practices